SEPTInvestingStart Free

DRMA SCHEDULE 13G: SEC filing

A joint filing agreement was

Filed with the SEC on · accession 0000921895-26-002901

DRMA filed a SCHEDULE 13G (schedule 13g) with the SEC on Nov 2, 2026. A joint filing agreement was filed under Schedule 13G by Michael Bigger and affiliated entities (Bigger Capital Fund LP, District 2 Capital entities) regarding their collective ownership of Dermata Therapeutics common stock. The stock moved -2.7% by the first close after the filing.

Summary of the filing

A joint filing agreement was filed under Schedule 13G by Michael Bigger and affiliated entities (Bigger Capital Fund LP, District 2 Capital entities) regarding their collective ownership of Dermata Therapeutics common stock. The filing is a passive ownership disclosure with no stated plans to influence company control.

For details, click here →

Key details

Issuer of securities subject to the schedule 13g filingDermata Therapeutics, Inc.
Reporting person / holderBigger Capital Fund L P
General partner of bigger capital fund l pBigger Capital Fund GP, LLC
Reporting person / holderDistrict 2 Capital Fund LP
Reporting person / holderDistrict 2 Capital LP
General partner of district 2 capital fund lpDistrict 2 GP LLC
Reporting person / holderDistrict 2 Holdings LLC
Managing member of bigger capital fund gp, llc and district 2 entitiesMichael Bigger

How DRMA stock reacted

Close before

$0.78

Oct 30, 2026

First close after

-2.74%

$0.75

5 trading days

—

Since filing

+9.51%

$0.85

✦ Ask GOAX AI about this filing — what it means for DRMA, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for DRMA?

Click here

Frequently asked questions

What did DRMA file with the SEC on Nov 2, 2026?

DRMA filed a SCHEDULE 13G (SEC filing). A joint filing agreement was filed under Schedule 13G by Michael Bigger and affiliated entities (Bigger Capital Fund LP, District 2 Capital entities) regarding their collective ownership of Dermata Therapeutics common stock. The filing is a passive ownership disclosure with no stated plans to influence company control.

How do I read a SCHEDULE 13G?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G (schedule 13g): A report the company filed with the SEC (the US market regulator).

How did DRMA stock react to this filing?

DRMA closed at $0.78 before the filing and $0.75 on Nov 2, 2026 (-2.74%).

Other DRMA SEC filings

Get alerts when DRMA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
DRMA overviewDRMA analysisDRMA newsLatest SEC filings